Accelerated Development Of Self-Amplifying mRNA (saRNA) Vaccines Using Microfluidics


The COVID-19 pandemic has unveiled the potential of messenger RNA (mRNA) based vaccines as an ideal platform for pandemic response. RNA vaccines mimic antigen structure and expression similar to natural infection without causing the disease, but allowing body to produce antibody response against future infection.

saRNAs have the potential for antigen sparring since lower doses elicit effective immune response compared to non-replicating mRNA vaccines. saRNAs are inherently more fragile than mRNA and are prone to degradation. Typical high shear manufacturing methods affect the potency.

Herein, we showcased the utility of microfluidics to enable low shear, rapid screening of preclinical candidates and the swift advancement to GMP-enabling studies.

access the Poster!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Cell & Gene